糖尿病黄斑水肿合并白内障手术:超声乳化联合地塞米松玻璃体内植入剂与标准超声乳化的比较
这项回顾性对比队列研究纳入非增殖性糖尿病视网膜病变合并黄斑水肿和白内障的患者,比较超声乳化联合地塞米松玻璃体内植入剂(DEX-I)与单纯超声乳化的功能和解剖结果。联合治疗组最佳矫正视力从第1个月显著提高并保持稳定,黄斑中心子区厚度从第2个月显著下降,且各时间点均显著低于单纯手术组。联合治疗组眼压随访期间显著升高但仍在正常范围内。
要点
- 联合DEX-I组最佳矫正视力从第1个月显著提高并保持稳定。
- 联合DEX-I组黄斑中心子区厚度从第2个月显著下降,各时间点均低于单纯手术组。
- 联合DEX-I组眼压显著升高但仍在正常范围内。
核心结论
- 在糖尿病合并黄斑水肿和白内障患者中,超声乳化联合DEX-I似乎有效、安全,在功能和断层参数上优于标准超声乳化。
研究设计与样本
- 回顾性、对比性队列研究,在意大利巴里大学医院眼科常规治疗的患者中开展。
- 纳入非增殖性糖尿病视网膜病变、黄斑水肿和白内障患者,联合DEX-I组23例,标准超声乳化组23例。
- 基线及术后每月评估最佳矫正视力、黄斑中心子区厚度和眼压,随访3个月。
- 采用t检验评估基线变化,并使用多水平回归模型(非结构化相关型矩阵)处理重复测量数据进行组内和组间统计分析。
主要发现
- 联合DEX-I组最佳矫正视力从第1个月显著提高(P=0.0005 vs 基线),后续随访保持稳定。
- 联合DEX-I组黄斑中心子区厚度从第2个月显著下降(P=0.049和P=0.04 vs 基线),各时间点均显著低于单纯手术组。
- 联合DEX-I组眼压随访期间显著升高(第3个月P=0.001 vs 基线),但仍在正常范围内。
- 单纯手术组最佳矫正视力和眼压术后无显著变化,黄斑中心子区厚度从第2个月升高(P=0.05 vs 基线)。
临床怎么用
- 对于糖尿病合并黄斑水肿和白内障需行超声乳化的患者,可考虑联合DEX-I以改善视力和控制黄斑厚度。
- 联合DEX-I治疗后需监测眼压变化,尽管本研究中升高仍在正常范围内。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 样本量较小(每组23例),随访时间仅3个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare functional and anatomical results of combined phacoemulsification and dexamethasone intravitreal implant (Ozurdex; DEX-I) with standard phacoemulsification in diabetic patients with cataract. METHODS: Retrospective, comparative, cohort study. Patients with nonproliferative diabetic retinopathy, macular edema, and cataract, treated routinely at the Eye Clinic, Azienda Ospedaliero Universitaria Policlinico, Bari, Italy with phacoemulsification associated with DEX-I (n = 23; Phaco-Dex) or standard phacoemulsification (n = 23; Phaco-alone). Best-correct visual acuity, central subfield thickness, and intraocular pressure were assessed at baseline and monthly for 3 months after surgery, and t-test was used to assess change from baseline. A multilevel regression model with an unstructured correlation-type matrix to account for repeated data measures was used for statistical analysis in and between groups. RESULTS: With Phaco-Dex, best-correct visual acuity increased significantly from the first month (P = 0.0005 vs. baseline) and remained stable at the following visits; central subfield thickness decreased significantly from Month 2 (P = 0.049 and P = 0.04 vs. baseline, respectively); at each timepoint, central subfield thickness was significantly lower in the Phaco-Dex group versus Phaco-alone. Intraocular pressure increased significantly during follow-up (P = 0.001 at Month 3 vs. baseline) but remained within the normal range. In the Phaco-alone group, best-correct visual acuity, and intraocular pressure did not show any significant changes after surgery, whereas central subfield thickness increased from Month 2 (P = 0.05 vs. baseline). CONCLUSION: In diabetic patients with macular edema and visually significant cataract, combined treatment with phacoemulsification and DEX-I seemed to be effective, safe, and superior to standard phacoemulsification considering both functional and tomographic parameters.
引用
- Furino C, Boscia F, Niro A, et al. DIABETIC MACULAR EDEMA AND CATARACT SURGERY: Phacoemulsification Combined With Dexamethasone Intravitreal Implant Compared With Standard Phacoemulsification. Retina. 2021. PMID: 32897932. doi:10.1097/IAE.0000000000002974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。